Long term follow-up of drug resistant and drug susceptible tuberculosis contacts in a Low incidence setting

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Johnston, James ^a,b   Admon, Andrew ^c   Ibrahim, Amir ^b   Elwood, Kevin ^a   Tang, Patrick ^b   Cook, Victoria ^a,b   Fitzgerald, Mark ^b  

^a BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Contact investigation; Epidemiology; Latent tuberculosis; Multidrug resistant; Tuberculosis

Indexed keywords

ISONIAZID;

ADULT; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; CANADA; CONTROLLED STUDY; DISEASE TRANSMISSION; DRUG RESISTANT TUBERCULOSIS; DRUG SENSITIVITY; DRUG SUSCEPTIBLE TUBERCULOSIS; EXTRAPULMONARY TUBERCULOSIS; FEMALE; HUMAN; INCIDENCE; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; REGISTER; TUBERCULIN TEST; TUBERCULOSIS;

ADOLESCENT; ADULT; ANTITUBERCULAR AGENTS; BRITISH COLUMBIA; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; TUBERCULIN TEST; TUBERCULOSIS, MULTIDRUG-RESISTANT; YOUNG ADULT;

EID: 84867646595     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-266     Document Type: Article

References (38)

1. World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB) 2010 Global report on surveillance and response 2011, Available from: http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf, World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB).
2. Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS One 2009, 4:e6914.
3. Gandhi NR, Nunn P, Dheda K, Schaaf HS, Zignol M, van Soolingen D, et al. Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis. Lancet 2010, 375:1830-1843.
4. Borrell S, Gagneux S. Infectiousness, reproductive fitness and evolution of drug-resistant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2009, 13:1456-1466.
5. Dye C, Williams BG, Espinal MA, Raviglione MC. Erasing the world's slow stain: strategies to beat multidrug-resistant tuberculosis. Science 2002, 295:2042-2046.
6. Garcia-Garcia ML, Ponce De Leon A, Jimenez-Corona ME, Jimenez-Corona A, Palacios-Martinez M, Balandrano-Campos S, et al. Clinical consequences and transmissibility of drug-resistant tuberculosis in southern Mexico. Arch Intern Med 2000, 160:630-636.
7. Toungoussova OS, Sandven P, Mariandyshev AO, Nizovtseva NI, Bjune G, Caugant DA. Spread of drug-resistant Mycobacterium tuberculosis strains of the Beijing genotype in the Archangel Oblast, Russia. J Clin Microbiol 2002, 40:1930-1937.
8. Burgos M, DeRiemer K, Small PM, Hopewell PC, Daley CL. Effect of drug resistance on the generation of secondary cases of tuberculosis. J Infect Dis 2003, 188:1878-1884.
9. Fandinho FC, Kritski AL, Hofer C, Junior Conde H, Ferreira RM, Saad MH, et al. RFLP patterns and risk factors for recent tuberculosis transmission among hospitalized tuberculosis patients in Rio de Janeiro, Brazil. Trans R Soc Trop Med Hyg 2000, 94:271-275.
10. Vazquez-Gallardo R, Anibarro L, Fernandez-Villar A, Diaz-Cabanela D, Cruz-Ferro E, del Molino ML P, et al. Multidrug-resistant tuberculosis in a low-incidence region shows a high rate of transmission. Int J Tuberc Lung Dis 2007, 11:429-435.
11. Godfrey-Faussett P, Sonnenberg P, Shearer SC, Bruce MC, Mee C, Morris L, et al. Tuberculosis control and molecular epidemiology in a South African gold-mining community. Lancet 2000, 356:1066-1071.
12. Nitta AT, Knowles LS, Kim J, Lehnkering EL, Borenstein LA, Davidson PT, et al. Limited transmission of multidrug-resistant tuberculosis despite a high proportion of infectious cases in Los Angeles County, California. Am J Respir Crit Care Med 2002, 165:812-817.
13. Attamna A, Chemtob D, Attamna S, Fraser A, Rorman E, Paul M, et al. Risk of tuberculosis in close contacts of patients with multidrug resistant tuberculosis: a nationwide cohort. Thorax 2009, 64:271.
14. Teixeira L, Perkins MD, Johnson JL, Keller R, Palaci M, Do Valle Dettoni V, et al. Infection and disease among household contacts of patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2001, 5:321-328.
15. Kritski AL, Marques MJ, Rabahi MF, Vieira MA, Werneck-Barroso E, Carvalho CE, et al. Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis. Am J Respir Crit Care Med 1996, 153:331-335.
16. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, et al. Tuberculosis burden in households of patients with multidrug-resistant and extensively drug-resistant tuberculosis: a retrospective cohort study. Lancet 2011, 377:147-152.
17. Singla N, Singla R, Jain G, Habib L, Behera D, et al. Tuberculosis among household contacts of multidrug-resistant tuberculosis patients in Delhi, India. Int J Tuberc Lung Dis 2011, 15(10):1326-1330.
18. Grandjean L, Crossa A, Gilman RH, Herrera C, Bonilla C, Jave O, et al. Tuberculosis in household contacts of multidrug-resistant tuberculosis patients. Int J Tuberc Lung Dis 2011, 15(9):1164-1169.
19. Vella V, Racalbuto V, Guerra R, Marra C, Moll A, Mhlanga Z, et al. Household contact investigation of multidrug-resistant and extensively drug-resistant tuberculosis in a high HIV prevalence setting. Int J Tuberc Lung Dis 2011, 15(9):1170-1175.
20. Bayona J, Chavez-Pachas A, Palacios E, Llaro K, Sapag R, Becerra MC. Contact investigation as a means of detection and timely treatment of persons with infectious multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2003, 7:S501-S509.
21. World Health Organization Antituberculosis drug resistance in the world: fourth global report 2008, Geneva: World Health Organization, World Health Organization.
22. BCCDC Annual Report 2004-2008 2008, Vancouver: BC Centre for Disease Control, BCCDC.
23. Fraser A, Paul M, Attamna A, Leibovici L. Treatment of latent tuberculosis in persons at risk for multidrug-resistant tuberculosis: systematic review. Int J Tuberc Lung Dis 2006, 10:19-23.
24. Long R, Ellis E. Canadian tuberculosis standards 2010, 6th, Tuberculosis committee of the Canadian thoracic society of the Canadian lung association, Available from: http://www.phac-aspc.gc.ca/tbpc-latb/pubs/tbstand07-eng.php.
25. Clinical and Laboratory Standards Institute (CLSI) Susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes; approved standard 2011, M24-A2. Wayne, PA, USA: CLSI, 2nd, Clinical and Laboratory Standards Institute (CLSI).
26. Zwerling A, Behr MAV, Brewer T, Menzies D, Pai M. BCG world atlas [internet] Available from: http://www.bcgatlas.org.
27. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC) This statement was endorsed by the council of the infectious diseases society of America. (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000, 161:S221-S247. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC).
28. World Health Organization Guidelines for the programmatic management of drug-resistant tuberculosis. [Internet] 2011, Available from: http://www.stoptb.org/assets/documents/resources/publications/technical/tb_guidelines.pdf, World Health Organization.
29. Fraser A, Paul M, Attamna A, Leibovici L. Drugs for preventing tuberculosis in people at risk of multiple-drug-resistant pulmonary tuberculosis. Cochrane Database of Systematic Reviews 2006, 19(2):CD005435.
30. Papastavros T, Dolovich LR, Holbrook A, Whitehead L, Loeb M. Adverse events associated with pyrazinamide and levofloxacin in the treatment of latent multidrug-resistant tuberculosis. CMAJ 2002, 167:131-136.
31. Horn DL, Hewlett D, Alfalla C, Peterson S, Opal SM. Limited tolerance of ofloxacin and pyrazinamide prophylaxis against tuberculosis. N Engl J Med 1994, 330:1241.
32. Younossian AB, Rochat T, Ketterer JP, Wacker J, Janssens JP. High hepatotoxicity of pyrazinamide and ethambutol for treatment of latent tuberculosis. Eur Respir J 2005, 26:462-464.
33. Cohen T, Lipsitch M, Walensky RP, Murray M. Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations. Proc Natl Acad Sci U S A 2006, 103:7042-7047.
34. Warren RM, Victor TC, Streicher EM, Richardson M, Beyers N, van Pittius NC G, et al. Patients with active tuberculosis often have different strains in the same sputum specimen. Am J Respir Crit Care Med 2004, 169:610-614.
35. van Rie A, Victor TC, Richardson M, Johnson R, van der Spuy GD, Murray EJ, et al. Reinfection and mixed infection cause changing Mycobacterium tuberculosis drug-resistance patterns. Am J Respir Crit Care Med 2005, 172:636-642.
36. Colijn C, Cohen T, Murray M. Latent coinfection and the maintenance of strain diversity. Bull Math Biol 2009, 71:247-263.
37. Behr MA. Tuberculosis due to multiple strains: a concern for the patient? A concern for tuberculosis control?. Am J Respir Crit Care Med 2004, 169:554-555.
38. Behr MA, Hopewell PC, Paz EA, Kawamura LM, Schecter GF, Small PM. Predictive value of contact investigation for identifying recent transmission of Mycobacterium tuberculosis. Am J Respir Crit Care Med 1998, 158:465-469.